Johnson and Johnson subsidiary to team up with University of Queensland spin-out to treat rheumatoid arthritis.

Dendright Pty, a biotech spin-out from the University of Queensland (UQ), has announced a collaboration with Johnson and Johnson subsidiary Janssen Biotech to tackle rheumatoid arthritis.

As part of the deal, the two will work together to move a new treatment, based on research from UQ’s Diamantina Institute, for the condition towards Phase I clinical trials. The deal is part of a developing relationship between the two firms after Janssen provided Dendright with seed financing last year.

The treatment differs…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?